OPKO Health Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: OPKO Health Inc.
Former names: Exegenics Inc Cytoclonal Pharmaceutics Inc
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Miami
Headquarters state / province: Florida
Headquarters country: United States
Fiscal year end: December
Ticker symbol: OPK
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000944809
EIN: 75-2402409

Board of directors

Follow this board

Alexis Borisy · Director Overboarded
Since 2023
Alice Lin-Tsing Yu · Director
Since 2023
Elias A. Zerhouni · Director · Vice Chairman and President
Since 2023
Gary J. Nabel · Director · Chief Innovation Officer
Since 2023
Jane Ph D. Hsiao · Director · Vice Chairman & CTO
Since 2023
John A. Paganelli · Director
Since 2023
Phillip Md Et Al Frost · Director · CEO & Chairman
Since 2023
Prem A. Lachman · Director
Since 2023
Richard C. Pfenniger Jr. · Director
Since 2023
Richard M. Krasno · Director
Since 2023
Roger Medel M.D. · Director
Since 2023
Steven D. Rubin · Director · Executive VP-Administration Overboarded
Since 2023
Subbarao Uppaluri V · Director
Since 2026

Chief executives

Phillip Md Et Al Frost · CEO & Chairman

Dates unknown

Director election results

Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

7 of this board's directors also sit on 15 other boards.

Shared director Other board Same sector

Cocrystal Pharma Inc.
via Phillip Md Et Al Frost, Richard C. Pfenniger Jr. and Steven D. Rubin
BioCardia Inc.
via Richard M. Krasno
Candel Therapeutics Inc.
via Gary J. Nabel
Danaher Corporation
via Elias A. Zerhouni
Eloxx Pharmaceuticals Inc.
via Steven D. Rubin
Entera Bio Ltd.
via Steven D. Rubin
Fluent Inc.
via Richard C. Pfenniger Jr.
GeneDx Holdings Corp.
via Richard C. Pfenniger Jr.
Niagen Bioscience Inc.
via Steven D. Rubin
Parabilis Medicines Inc.
via Alexis Borisy
Red Violet Inc.
via Steven D. Rubin
Relay Therapeutics Inc.
via Alexis Borisy
Revolution Medicines Inc.
via Alexis Borisy
SIGA Technologies Inc.
via Gary J. Nabel
Tango Therapeutics Inc.
via Alexis Borisy

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $3,208,366; 34 purchases by 2 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Jul 24, 2026	Adam Logal Officer (Sr. Vice President, CFO)	Shares withheld for tax	−53,266	$1.22	$64,985
Jul 24, 2026	Steven D. Rubin Director, Officer (Executive VP-Administration)	Shares withheld for tax	−53,266	$1.22	$64,985
Mar 20, 2026	John A. Paganelli Director	Open-market purchase	+10,000	$1.14	$11,400
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+102,371	$1.30	$133,082
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+3,894	$1.32	$5,140
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+89,375	$1.33	$118,869
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+191,490	$1.33	$254,682
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+192,870	$1.34	$258,446
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+119,129	$1.32	$157,250
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+47,105	$1.33	$62,650
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+211,948	$1.33	$281,891
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+161,818	$1.34	$216,836
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+24,579	$1.34	$32,936
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+1,757	$1.35	$2,372
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+13,664	$1.35	$18,446

Reviews (0)

No reviews yet. Be the first to write one.